Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
about
Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraineTreatment of migraine attacks based on the interaction with the trigemino-cerebrovascular systemActivation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and functionBIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37)Understanding migraine: Potential role of neurogenic inflammationCortical spreading depression in migraine-time to reconsider?The TRPA1 channel in migraine mechanism and treatmentG protein-coupled receptors: what a difference a 'partner' makesMolecular factors in migraineCurrent Understanding on Pain Mechanism in Migraine and Cluster HeadacheCharacterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neuronesImmunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculatureCGRP may play a causative role in migraineCalcitonin gene-related peptide: physiology and pathophysiologyNeuronal signal substances as biomarkers of migraineOn serotonin and migraine: a clinical and pharmacological reviewRamping it up: RAMP1 and the implications for migraineNeuropeptides in migraine and cluster headacheRole of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized ratsPharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonistThe anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigsPharmacological evidence for CGRP uptake into perivascular capsaicin sensitive nerve terminalsTonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexesMontelukast in the prophylaxis of migraine: a potential role for leukotriene modifiersNeurovascular contributions to migraine: Moving beyond vasodilationStudy of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized ratEndosomal proteolysis regulates calcitonin gene-related peptide responses in mesenteric arteriesReceptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonistsOrofacial pain management: current perspectives.Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation.A Potential Preclinical Migraine Model: CGRP-Sensitized Mice.Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine.Effect of cortical spreading depression on activity of trigeminovascular sensory neurons.Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat.Capsaicin-sensitive neurogenic sensory vasodilatation in the dura mater of the rat.A fresh look at migraine therapy. New treatments promise improved management.Possible role of histamine (H1- and H2-) receptors in the regulation of meningeal blood flow.Calcitonin gene-related peptide receptor antagonists for the treatment of migraine: a patent review.Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine
P2860
Q24632671-BE7A71C9-3CF2-4BF6-BEB5-24A798D41D01Q24646305-ED85C272-6307-415C-BC47-B9E502798E19Q24671891-B7DB3EE3-86D8-454F-A0D6-51EBD9279F07Q24677292-E6A73FAC-A9C8-4C9A-AFD5-B9469A1CD53EQ26747000-6353C0B0-60C6-4DD5-A77C-6B3F63898020Q26801817-BFE5DF62-88FC-43D9-BD80-32715D51A5EDQ27016641-8698AB68-319D-4509-BB30-A725BDD1B59AQ27023482-74A1E1C9-3C65-4D37-9AA5-D5D0CE99B63FQ28078828-5F3246A1-A551-4C58-A51D-A46B410EA734Q28079173-82BFF4F0-DB07-4198-AFFB-D51842D7F065Q28191541-55E2F47D-85A9-40C3-950C-30EDF6905E21Q28215715-4BF43B38-FA03-48DF-9B1D-9CB87F098EBBQ28216666-1F37813F-4E35-4787-A904-FE9CC8E8E1E4Q28249298-CE626EED-87D8-4BA1-BD17-3F008564646FQ28254002-63E9E258-057C-493B-AB13-A242D3FA464AQ28263827-FEAD85A9-A7CA-4F56-A0D1-FEAF333FD155Q28266882-60AD451F-E436-40A6-897E-7D889D5F24C6Q28305727-D408B0C0-F610-4686-BB1B-6FCA0637C335Q28343904-BF683D4C-890C-481D-8464-1F29655FE03DQ28344003-E0802755-7DB2-48B5-963B-9A31F4E5C1FDQ28345449-EB0AF387-6350-42DD-B0F7-7616498B17A4Q28354243-846A5280-4F0E-4C1D-8F05-E48DCF80F1EDQ28361230-34ACA13E-E7A9-4ED9-8AF3-4939C27FBC68Q28376497-CF574994-A1A1-4AAE-91D9-905B403F211CQ28392631-324A6793-796F-4411-A397-B1F5044E12F2Q28565111-F8FA7154-57A6-4FA8-9F24-9178A9DECEA3Q28577195-393228B0-A082-486A-9EE4-CA9E74AF777FQ28577506-DF019001-915E-4FFE-85B8-F3AE621A0A92Q30442178-D77B9349-0F33-44C2-8C1B-4D5ABF6B82C5Q30466408-34C7E4C2-AB93-4EDB-8CA5-47E07370A3C7Q30482553-3F874267-9899-4C13-9989-43B22713BA18Q30496689-98CC2EE1-C279-47AB-827A-3B5651170B67Q30793385-1328EF39-5046-4252-846C-0894DB979532Q30853246-98B6AE9C-9CE0-4E16-9391-08CBFE583AE3Q30979297-0C2DE321-1813-4083-86F5-544BD5CA4195Q31992250-B01CEDB9-5216-4085-9BEE-4FB4D74CEF2EQ33185056-C2833270-847D-4FAD-9AD0-0C6CBD02946CQ33516651-22625767-F11E-424B-B38A-0DFA3A1E4385Q33524521-73606BF2-6C8B-44F8-8055-A6878741BCDEQ33630515-667C7B4A-5236-4817-B2E5-37E0046CA098
P2860
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
description
1990 nî lūn-bûn
@nan
1990 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Vasoactive peptide release in ...... umans during migraine headache
@ast
Vasoactive peptide release in ...... umans during migraine headache
@en
Vasoactive peptide release in ...... umans during migraine headache
@nl
type
label
Vasoactive peptide release in ...... umans during migraine headache
@ast
Vasoactive peptide release in ...... umans during migraine headache
@en
Vasoactive peptide release in ...... umans during migraine headache
@nl
prefLabel
Vasoactive peptide release in ...... umans during migraine headache
@ast
Vasoactive peptide release in ...... umans during migraine headache
@en
Vasoactive peptide release in ...... umans during migraine headache
@nl
P3181
P356
P1433
P1476
Vasoactive peptide release in ...... umans during migraine headache
@en
P2093
P3181
P356
10.1002/ANA.410280213
P407
P577
1990-08-01T00:00:00Z